UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa
Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study supports the dose-finding results from the recent IASOS Phase 2b […]
Announcement of topline results from the PROTECT-V platform study investigating niclosamide nasal spray to prevent COVID-19 infection in vaccinated but highly vulnerable patients
Hellerup, Denmark, June 16, 2023 – UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced topline results from the niclosamide arm […]
UNION therapeutics to present at 4th Annual Dermatology Drug Development Summit Europe
Hellerup, Denmark, May 10, 2023 – UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim […]
UNION therapeutics to participate at Kempen Life Science Conference
Hellerup, Denmark, April 21, 2023 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced participation at the Kempen […]
UNION therapeutics announces presentation of Phase 2b results with oral orismilast at the AAD Annual Meeting 2023
Late-breaking presentation of results from the Phase 2b IASOS study of oral orismilast in psoriasis to be presented at the American Academy of Dermatology (AAD) Annual Meeting 2023 Positive topline […]
UNION therapeutics announces full-year results for 2022 and provides business update
Hellerup, Denmark, February 9, 2023, – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces full-year results for the […]
UNION therapeutics announces presentation of preliminary data on Phase 2a investigator-initiated study with orismilast at the 12th EHSF Conference and provides study update
Poster presentation of preliminary data from the Phase 2a investigator-initiated study OSIRIS at the 12th EHSF Conference Hidradenitis suppurativa (HS) is a scarring, painful, inflammatory skin disease with few or […]
UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa
FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by moderate to severe hidradenitis suppurativa […]
UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis
Primary endpoint at week 16 was met for all three active doses of oral orismilast in moderate to severe patients with psoriasis. Statistical significance reached already at the first […]
First large-scale analysis confirms that vulnerable patients remain at increased fatality to COVID-19 despite availability of vaccines
Analysis includes data from UK Kidney Association (UKKA) on 9,388 COVID-19 cases among kidney patients in the UK of which 924 were fatal (Dec 2020 to March 2022) The analyses […]